WHY should you choose EndoPredict® over other tests?
Frequently Asked Questions
EndoPredict is a second-generation genomic test used to predict the likelihood of breast cancer recurrence and determine if a patient will benefit from chemotherapy.
It is designed for women with early-stage, ER-positive, HER2-negative invasive breast cancer, including those with up to three positive lymph nodes.
Results are typically available within 7 to 10 working days, as the testing can be performed locally in specialized UAE labs.
No, it uses the “fixed” tissue sample (FFPE) already taken during your initial biopsy or tumor removal surgery.
An EPclin Risk Score below 3.3 is considered low risk, meaning there is less than a 10% chance of recurrence over 10 years without chemotherapy.
Unlike first-generation tests, EndoPredict provides information on both early (0–10 years) and late (up to 15 years) recurrence risk, and it is validated for both node-negative and node-positive patients.
It is “second-generation” because it combines molecular gene expression data with clinical factors like tumor size and nodal status to create a more accurate “EPclin” score.
Yes. If the test returns a “Low Risk” result, clinical guidelines suggest that the absolute benefit of chemotherapy is minimal, allowing many patients to safely choose hormone therapy alone.
Yes, it is specifically designed to help doctors decide if a patient needs extended endocrine (hormone) therapy beyond the standard five-year mark.
Yes, clinical studies have validated EndoPredict’s accuracy for both premenopausal and postmenopausal women.
The test analyzes 12 genes in total: 8 cancer-related genes, 3 reference genes for normalization, and 1 control gene.
The EPclin score is a calculated value that integrates the 12-gene molecular score with the patient’s tumor size and lymph node status
It is highly accurate and backed by Level 1A clinical evidence, included in major international guidelines like NCCN, ASCO, and St. Gallen.
A high-risk score ($>3.3$) indicates a higher probability of recurrence. In this case, your oncologist will likely recommend adding chemotherapy to your treatment plan to lower that risk.